{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:57:36Z","timestamp":1789178256842,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,14]]},"DOI":"10.7759\/cureus.58253","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T22:06:20Z","timestamp":1713132380000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Hiroaki","family":"Ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Munechika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tobino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Muarakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-48. 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals M","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014, 383:1503-16. 10.1016\/S0140-6736(13)61048-X","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0365-3","article-title":"Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report","volume":"6","author":"Sadaat M","year":"2018","unstructured":"Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018, 6:49. 10.1186\/s40425-018-0365-3","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx113","article-title":"Pembrolizumab associated hemophagocytic lymphohistiocytosis","volume":"28","author":"Shah D","year":"2017","unstructured":"Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017, 28:1403. 10.1093\/annonc\/mdx113","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16630","article-title":"Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review","volume":"189","author":"Dupr\u00e9 A","year":"2020","unstructured":"Dupr\u00e9 A, Michot JM, Schoeffler A, et al.. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. Br J Haematol. 2020, 189:985-92. 10.1111\/bjh.16630","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16079","article-title":"Encephalitis associated with hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitors: an unfamiliar spin-off","volume":"13","author":"Ghous G","year":"2021","unstructured":"Ghous G, Shoukat HM, Tarar ZI, Zafar MU, McGreevy JW. Encephalitis associated with hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitors: an unfamiliar spin-off. Cureus. 2021, 13:e16079. 10.7759\/cureus.16079","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski MA","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, et al.. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018, 378:2288-301. 10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer A","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al.. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017, 389:255-65. 10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03585-3","article-title":"Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature","volume":"16","author":"Rubio-Perez J","year":"2022","unstructured":"Rubio-Perez J, Rodr\u00edguez-Perez \u00c1R, D\u00edaz-Bl\u00e1zquez M, Moreno-Garc\u00eda V, D\u00f3mine-G\u00f3mez M. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature. J Med Case Rep. 2022, 16:365. 10.1186\/s13256-022-03585-3","journal-title":"J Med Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100263","article-title":"Marked, lasting disease regression and concomitantly induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in a patient with lung adenocarcinoma and autoantibodies receiving atezolizumab plus chemotherapy: a case report","volume":"3","author":"Endo Y","year":"2022","unstructured":"Endo Y, Inoue Y, Karayama M, et al.. Marked, lasting disease regression and concomitantly induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in a patient with lung adenocarcinoma and autoantibodies receiving atezolizumab plus chemotherapy: a case report. JTO Clin Res Rep. 2022, 3:100263. 10.1016\/j.jtocrr.2021.100263","journal-title":"JTO Clin Res Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda R","year":"2019","unstructured":"Noseda R, Bertoli R, M\u00fcller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019, 7:117. 10.1186\/s40425-019-0598-9","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1001-18","article-title":"Pembrolizumab-induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in non-small cell lung cancer","volume":"58","author":"Okawa S","year":"2019","unstructured":"Okawa S, Kayatani H, Fujiwara K, et al.. Pembrolizumab-induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in non-small cell lung cancer. Intern Med. 2019, 58:699-702. 10.2169\/internalmedicine.1001-18","journal-title":"Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3889-19","article-title":"Hemophagocytic lymphohistiocytosis in a patient with rheumatoid arthritis on pembrolizumab for lung adenocarcinoma","volume":"59","author":"Akagi Y","year":"2020","unstructured":"Akagi Y, Awano N, Inomata M, et al.. Hemophagocytic lymphohistiocytosis in a patient with rheumatoid arthritis on pembrolizumab for lung adenocarcinoma. Intern Med. 2020, 59:1075-80. 10.2169\/internalmedicine.3889-19","journal-title":"Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13954","article-title":"Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors","volume":"12","author":"Kurozumi A","year":"2021","unstructured":"Kurozumi A, Takahashi H, Watanabe T, Iwasaki Y. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors. Thorac Cancer. 2021, 12:1625-8. 10.1111\/1759-7714.13954","journal-title":"Thorac Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-154","article-title":"Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review","volume":"11","author":"Wei Y","year":"2022","unstructured":"Wei Y, He W, Sun W, et al.. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review. Transl Cancer Res. 2022, 11:2960-6. 10.21037\/tcr-22-154","journal-title":"Transl Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1117","article-title":"Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis in a patient with non-small cell lung carcinoma","volume":"11","author":"Oyama S","year":"2023","unstructured":"Oyama S, Shirai T, Abe Y, et al.. Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis in a patient with non-small cell lung carcinoma. Respirol Case Rep. 2023, 11:e01117. 10.1002\/rcr2.1117","journal-title":"Respirol Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002855","article-title":"Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report","volume":"9","author":"Sackstein P","year":"2021","unstructured":"Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021, 9:e002855. 10.1136\/jitc-2021-002855","journal-title":"J Immunother Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0582-4","article-title":"Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report","volume":"7","author":"Honjo O","year":"2019","unstructured":"Honjo O, Kubo T, Sugaya F, et al.. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019, 7:97. 10.1186\/s40425-019-0582-4","journal-title":"J Immunother Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1076","article-title":"Immune-related aseptic meningitis diagnosed by Cube FLAIR on enhanced magnetic resonance imaging for a lung cancer patient administered atezolizumab: a case report","volume":"11","author":"Kuroda R","year":"2023","unstructured":"Kuroda R, Nakagawa H, Uchida Y, et al.. Immune-related aseptic meningitis diagnosed by Cube FLAIR on enhanced magnetic resonance imaging for a lung cancer patient administered atezolizumab: a case report. Respirol Case Rep. 2023, 11:e01076. 10.1002\/rcr2.1076","journal-title":"Respirol Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00947-w","article-title":"Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review","volume":"38","author":"Ogawa K","year":"2020","unstructured":"Ogawa K, Kaneda H, Kawamoto T, et al.. Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review. Invest New Drugs. 2020, 38:1901-5. 10.1007\/s10637-020-00947-w","journal-title":"Invest New Drugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100012","article-title":"Atezolizumab-induced aseptic meningitis in patients with NSCLC","volume":"1","author":"Toyozawa R","year":"2020","unstructured":"Toyozawa R, Haratake N, Toyokawa G, et al.. Atezolizumab-induced aseptic meningitis in patients with NSCLC. JTO Clin Res Rep. 2020, 1:100012. 10.1016\/j.jtocrr.2020.100012","journal-title":"JTO Clin Res Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium","volume":"57","author":"Venkatesan A","year":"2013","unstructured":"Venkatesan A, Tunkel AR, Bloch KC, et al.. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013, 57:1114-28. 10.1093\/cid\/cit458","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.21037\/qims-22-1151","article-title":"Central nervous system involvement in adult-onset hemophagocytic lymphohistiocytosis secondary to lymphoma: a case presentation and literature analysis","volume":"13","author":"He T","year":"2023","unstructured":"He T, Zhong Y, Li H, et al.. Central nervous system involvement in adult-onset hemophagocytic lymphohistiocytosis secondary to lymphoma: a case presentation and literature analysis. Quant Imaging Med Surg. 2023, 13:4032-40. 10.21037\/qims-22-1151","journal-title":"Quant Imaging Med Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/231309-a-case-report-of-hemophagocytic-lymphohistiocytosis-and-meningitis-due-to-atezolizumab-treatment-for-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T22:06:25Z","timestamp":1713132385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/231309-a-case-report-of-hemophagocytic-lymphohistiocytosis-and-meningitis-due-to-atezolizumab-treatment-for-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,14]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.58253","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,14]]}}}